Publications for Lars-Åke Levin
Co-author map based on ISI articles 2007-
Publications mentioned in social media 9 times*
Journal Articles
Thomas Davidson, Magnus Husberg, Magnus Janzon, Jonas Oldgren and Lars-Åke Levin
Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden
European Heart Journal, 2013, 34(3), 177-183.
Web of Science® Times Cited: 1 |
Leif Friberg, Johan Engdahl, Viveka Frykman, Emma Svennberg, Lars-Åke Levin and Marten Rosenqvist
Population screening of 75- and 76-year-old men and women for silent atrial fibrillation (STROKESTOP)
Europace, 2013, 15(1), 135-140.
Web of Science® Times Cited: 3 |
Emelie Heintz, Marieke Krol and Lars-Åke Levin
The impact of patients' subjective life expectancy on time trade-off valuations
Medical decision making, 2013, 33(2), 261-270.
|
Ola Granström, Lars-Åke Levin and Martin Henriksson
Cost-effectiveness of candesartan versus losartan in the primary preventive treatment of hypertension.
ClinicoEconomics and outcomes research : CEOR, 2012, 4, 313-322.
|
Talitha I Verhoef, William K Redekop, Rianne M F van Schie, Samira Bayat, Ann K Daly, Mary Geitona, Elisabeth Haschke-Becher, Dyfrig A Hughes, Farhad Kamali, Lars-Åke Levin, Vangelis G Manolopoulos, Munir Pirmohamed, Uwe Siebert, Julia C Stingl, Mia Wadelius, Anthonius de Boer and Anke-Hilse Maitland-van der Zee
Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs
Pharmacogenomics (London), 2012, 13(12), 1405-1417.
|
Emelie Heintz, Ann-Britt Wiréhn, Beatrice Bourghardt Peebo, Ulf Rosenqvist and Lars-Åke Levin
QALY Weights for Diabetic Retinopathy: A Comparison of Health State Valuations with HUI-3, EQ-5D, EQ-VAS, and TTO
Value in Health, 2012, 15(3), 475-484.
Web of Science® Times Cited: 1 |
Billie Pettersson, Mikael Hoffmann, Per Wändell and Lars‐Åke Levin
Utilization and Costs of Glucose‐ lowering Therapies following Health Technology Assessment for the new reimbursement scheme in Sweden
Health Policy, 2012, 108(2-3), 207-215.
|
U Alstrom, Lars-Åke Levin, E Stahle, Rolf Svedjeholm and O Friberg
Cost analysis of re-exploration for bleeding after coronary artery bypass graft surgery
British Journal of Anaesthesia, 2012, 108(2), 216-222.
|
Billie Pettersson, Mikael Hoffmann, Per Wandell and Lars-Åke Levin
Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden
Health Policy, 2012, 104(1), 84-91.
Web of Science® Times Cited: 2 |
Thomas Davidson, Magnus Husberg, Magnus Janzon and Lars-Åke Levin
The Cost of Thromboembolic Events and their Prevention among Patients with Atrial Fibrillation
Journal of Atrial Fibrillation, 2011, 2(4), 00-00.
|
Nathalie Eckard, Magnus Janzon and Lars-Åke Levin
Compilation of cost-effectiveness evidence for different heart conditions and treatment strategies
Scandinavian Cardiovascular Journal, 2011, 45(2), 72-76.
Fulltext  |
Lars Grip, Bertil Lindahl, Lars-Åke Levin, Christina Karvinge, Kristina Eklund and Lars Wallentin
From European to National guidelines on heart disease
SCANDINAVIAN CARDIOVASCULAR JOURNAL, 2011, 45(1), 3-13.
Web of Science® Times Cited: 1 |
M Henriksson, D Russell, J Bodegard, S Kjeldsen, P Hasvold, J Stalhammar and Lars-Åke Levin
Health-care costs of losartan and candesartan in the primary treatment of hypertension
JOURNAL OF HUMAN HYPERTENSION, 2011, 25(2), 130-136.
Web of Science® Times Cited: 2 |
Emelie Heintz, Ann-Britt Wiréhn, Bourghardt B Peebo, U Rosenqvist and Lars-Åke Levin
Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden
Diabetologia, 2010, 53(10), 2147-2154.
Web of Science® Times Cited: 12 |
Mikael Aasa, Martin Henriksson, Mikael Dellborg, Lars Grip, Johan Herlitz, Lars-Åke Levin, Leif Svensson and Magnus Janzon
Cost and health outcome of primary percutaneous coronary intervention versus thrombolysis in acute ST-segment elevation myocardial infarction-Results of the Swedish Early Decision reperfusion Study (SWEDES) trial
AMERICAN HEART JOURNAL, 2010, 160(2), 322-328.
Web of Science® Times Cited: 4 |
Thomas Davidson and Lars-Ake Levin
Is the societal approach wide enough to include relatives?: incorporating relatives' costs and effects in a cost-effectiveness analysis.
Applied Health Economics and Health Policy, 2010, 8(1), 25-35.
|
L. Grip, K. Eklund, L. Weilandt, Lars-Åke Levin and B. Lindahl
Ingen evidens för nyttan av ny policy vid asymtomatisk preexcitation
Läkartidningen, 2009, 106(50), .
|
Nathalie Eckard, Thomas Davidson, Håkan Walfridsson and Lars-Åke Levin
Cost-Effectiveness of Catheter Ablation Treatment for Patients with Symptomatic Atrial Fibrillation
Journal of Atrial Fibrillation, 2009, 1(8), 461-470.
|
Emelie Heintz, Thor-Henrik Brodtkorb, Nina Nelson and Lars-Åke Levin
The long-term cost-effectiveness of fetal monitoring during labour: a comparison of cardiotocography complemented with ST analysis versus cardiotocography alone
British Journal of Obstetrics and Gynecology, 2008, 115, 1676-1687.
Web of Science® Times Cited: 10 |
Thomas Davidson and Lars-Åke Levin
Do individuals consider expected income when valuing health states?
International Journal of Technology Assessment in Health Care, 2008, 24(4), 488-494.
Web of Science® Times Cited: 4 |
Thomas Davidson, Barbro Krevers and Lars-Åke Levin
In pursuit of QALY weights for relatives: Empirical estimates in relatives caring for older people
European Journal of Health Economics, 2008, 9(3), 285-292.
Web of Science® Times Cited: 2 |
Urban Alehagen, Mikael Rahmqvist, Thomas Paulsson and Lars-Åke Levin
Quality-adjusted life year weights among elderly patients with heart failure
European journal of heart failure, 2008, 10(10), 1033-1039.
Web of Science® Times Cited: 6 |
Douglas Lundin, Per Carlsson, Lars-Åke Levin and Ulf Persson
Analys av kostnadseffektivitet i samhällsekonomiskt perspektiv
Läkartidningen, 2006, 103(47), 3716-3718.
|
Örjan Friberg, Lars-Göran Dahlin, Lars-Åke Levin, Anders Magnusson, Hans Granfeldt, Jan Källman and Rolf Svedjeholm
Cost effectiveness of local collagen-gentamicin as prophylaxis for sternal wound infections in different risk groups
Scandinavian Cardiovascular Journal, 2006, 40(2), 117-125.
Web of Science® Times Cited: 12 |
Urban Alehagen, G Lindstedt, Lars-Åke Levin and Ulf Dahlström
Risk of cardiovascular death in elderly patients with possible heart failure. B-type natriuretic peptide (BNP) and the aminoterminal fragment of ProBNP (N-terminal proBNP) as prognostic indicators in a 6-year follow-up of a primary care population
International Journal of Cardiology, 2005, 100(1), 125-133.
Web of Science® Times Cited: 26 |
Urban Alehagen, G. Lindstedt, Lars-Åke Levin and Ulf Dahlström
The risk of cardiovascular death in elderly patients with possible heart failure: results from a 6-year follow-up of a Swedish primary care population
International Journal of Cardiology, 2005, 100(1), 17-27.
Web of Science® Times Cited: 10 |
Magnus Janzon, Lars-Åke Levin and Eva Swahn
Invasive treatment in unstable coronary artery disease promotes health-related quality of life: results from the FRISC II trial
American Heart Journal, 2004, 148(1), 114-121.
Web of Science® Times Cited: 17 |
Anna Strömberg, J. Mårtensson, Bengt Fridlund, Lars-Åke Levin, Jan-Erik Karlsson and Ulf Dahlström
Nurse-led heart failure clinics improve survival and self-care behaviour in patients with heart failure: Results from a prospective, randomised trial
European Heart Journal, 2003, 24(11), 1014-1023.
Web of Science® Times Cited: 149 |
Magnus Janzon, Lars-Åke Levin and Eva Swahn
Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial
Heart, 2003, 89(3), 287-292.
Web of Science® Times Cited: 4 |
Agneta Andersson, John Carstensen, Lars-Åke Levin and Bengt Göran Emtinger
Costs of informal care for patients in advanced home care: a population based study
International Journal of Technology assessment in Health Care, 2003, 19(4), 656-663.
Web of Science® Times Cited: 10 |
Magnus Janzon, Lars-Åke Levin and Eva Swahn
Cost-effectiveness of an invasive strategy in unstable coronary artery disease: results from the FRISC II invasive trial
European Heart Journal, 2002, 23(1), 31-40.
Web of Science® Times Cited: 26 |
Agneta Andersson, Lars-Åke Levin and Bengt Göran Emtinger
The economic burden of informal care
International Journal of Technology Assessment in Health Care, 2002, 18(1), 46-54.
Web of Science® Times Cited: 13 |
Agneta Andersson, Lars-Åke Levin, Birgitta Öberg and Linda Månsson
Health care and social welfare costs in home-based and hospital-based rehabilitation after stroke
Scandinavian Journal of Caring Sciences, 2002, 16(4), 386-392.
Web of Science® Times Cited: 10 |
Lars-Åke Levin and D Bergqvist
Cost effectiveness of desirudin compared with a low molecular weight heparin in the prevention of deep vein thrombosis after total hip replacement surgery
PharmacoEconomics (Auckland), 2001, 19(5 II), 589-597.
Web of Science® Times Cited: 10 |
Agneta Andersson, K. Ström, H. Brodin, M. Alton, G. Boman, P. Jakobsson, A. Lindberg, M. Uddenfeldt, H. Walter and Lars-Åke Levin
Domiciliary liquid oxygen versus concentrator treatment in chronic hypoxaemia: a cost-utility analysis
European Respiratory Journal, 1998, 12(6), 1284-1289.
|
Books
Anthologies
Chapters in Books
Conference Articles
M. Henriksson, Elisabet Nikolic, Magnus Janzon, O. Hauch, Lars-Åke Levin and L. Wallentin
LONG-TERM COSTS AND HEALTH OUTCOMES OF TREATING ACUTE CORONARY SYNDROME PATIENTS WITH TICAGRELOR BASED ON THE EU LABEL - COST-EFFECTIVENESS ANALYSIS BASED ON THE PLATO STUDY in VALUE IN HEALTH, vol 14, issue 3, pp A40-A40
VALUE IN HEALTH, 2011.
Web of Science® Times Cited: 2
|
H Patel, M Schaufelberger, Tiny Jaarsma and Lars-Åke Levin
Are there enough hospital beds to care for an aging population with chronic diseases in the furute? - is there another option? (oral presentation)
Första Nationella Hälsoekonomiska konferensen (SHEA), Göteborg, 2011.
|
Josefine Persson, Gunilla Forsberg-Wärleby, Ingvar Karlberg, Christian Blomstrand and Lars-Åke Levin
Anhörigas stöd till yngre strokepatienter i ett långtidsperspektiv (muntlig presentation)
Första Nationella Hälsoekonomiska konferensen (SHEA), Göteborg, 2011.
|
Magnus Janzon, Elisabet Nikolic, Martin Henriksson, Lars-Åke Levin, Ole Hauch, DB Mark, P. Cowper, P. Kaul, RA. Harrington, J. Horrow and Lars Wallentin
Health Economics in the PLATelet Inhibition and Patient Outcomes (PLATO) Randomized Trial: Report on Within Trial Resource Use Patterns
The American Heart Association 2010 Scientific Sessions, Chicago, IL, USA, November 13-17 2010, 2010.
|
Emelie Heintz, Bourghardt B. Peebo, Ann-Britt Wiréhn, U. Rosenqvist and Lars-Åke Levin
QUALITY-ADJUSTED LIFE-YEAR (QALY) WEIGHTS ASSOCIATED WITH DIFFERENT SEVERITY LEVELS OF DIABETIC RETINOPATHY in VALUE IN HEALTH, vol 13, issue 7, pp A297-A297
VALUE IN HEALTH, 2010.
|
M. Henriksson, D. Russell, S.E. Kjeldsen, J. Bodegard, P. Hasvold and Lars-Åke Levin
HEALTH CARE COSTS OF LOSARTAN AND CANDESARTAN IN THE PRIMARY TREATMENT OF HYPERTENSION in JOURNAL OF HYPERTENSION, vol 28, issue , pp E240-E241
JOURNAL OF HYPERTENSION, 2010.
|
Nathalie Eckard, Magnus Janzon and Lars-Åke Levin
Communicating cost-effectiveness ratios to decision makers - the case of the Swedish national guidelines for hearts diseases (Abstract)
Value in Health, 2010.
|
Nathalie Eckard, Magnus Janzon and Lars-Åke Levin
Communicating cost-effectiveness ratios to decision makers - the case of the Swedish national guidelines for heart diseases (Poster)
ISPOR 13th Annual European Congress. Prag Tjeckien, 2010.
|
Thomas Davidson, Magnus Husberg, Magnus Janzon and Lars-Åke Levin
The cost of atrial fibrillation in Sweden (Poster)
Value in Health, 2010.
|
Martin Henriksson, Magnus Janzon, M. Aasa, Elisabet Lundborg (Nikolic), L. Svensson, J. Herlitz, L. Grip and Lars-Åke Levin
Cost-effectiveness of very early treatment strategies for acute ST-elevation myocardial infarction based on the Swedish early decision (SWEDES) reperfusion trial (oral presentation)
SMDM Europe,2008, 2008.
|
Nathalie Eckard, Martin Henriksson, Thomas Davidson, Håkan Walfridsson and Lars-Åke Levin
Cost-effectiveness of catheter ablation versus antiarrhytmic drugs for patients with symptomatic atrial fibrillation (oral presentation)
SMDM Europe,2008, 2008.
|
Thomas Davidson and Lars-Åke Levin
Do individuals consider expected income when valueing health states?
iHEA, the 6th world congress on health economics,2007, 2007.
|
Magnus Janzon, Mikael Aasa, Johan Lyth, Leif Svensson, Johan Herlitz, Lars Grip and Lars-Åke Levin
Cost and effectiveness comparison of very early treatment with primary percutaneous coronary intervention facilitated with abciximab or thrombolytic therapy for acute ST-elevation myocardial infarction
ACC,2007, 2007.
|
Magnus Janzon, Lars-Åke Levin and Eva Swahn
Invasive treatment in non ST elevation acute coronary syndorme promotes long-term health related quality of life - results from the FRISC II trial
ACC, New Orleans, LA,2007, 2007.
|
Thomas Davidson, Barbro Krevers and Lars-Åke Levin
Identification and Estimation of Relatives' QALY Weights for Use in Health Economic Evaluations
ECHE, 6th European Conference in Health Economics,2006, 2006.
|
Thomas Davidson and Lars-Åke Levin
Using the costs of added life-years in a cost-effectiveness analysis
HTAi, 2nd Annual HTAi Meeting - Bringing HTA into practice,2005, 2005.
|
Lars-Åke Levin, M Janzon and Eva Swahn
Long-term cost-effectiveness of invasive strategy in patient with unstable coronary artery disease results from the FRISC-II trial
Value in Health, 2003.
|
Per Carlsson, Erling Karlsson, Christina Kärvinge and Lars-Åke Levin
National guidelines for heart diseases in Sweden - A model for oper vertical priority-setting
ISTACH annual conference, Canmore, Canada 22-25 June 2003 (poster presentation),2003, 2003.
|
A Stromberg, J Martensson, B Fridlund, JE Karlsson, Lars-Åke Levin and Ulf Dahlström
Follow up at a nurse-led heart failure clinic after hospitalization, effects on morbidity, mortality and self-care behavior. Results from a randomized study
Circulation, 2002.
|
Magnus Janzon, Martin Henriksson, Lars-Åke Levin and Eva Swahn
Quality of life in unstable angina - Individual and public preferences differ in levels but are similar when measuring changes over time
European Heart Journal, 2002.
|
A Stromberg, J Martensson, B Fridlund, JE Karlsson, Lars-Åke Levin and Ulf Dahlström
Effects of follow-up after hospitalisation at a nurse-led heart failure clinic: a randomiced trial
European Heart Journal, 2002.
|
Magnus Janzon, Martin Henriksson, Lars-Åke Levin and Eva Swahn
Quality of life in unstable angina. Individual and public preferences differ in levels but are similar when measuring changes over time
ISTAHC-konferens, Berlin, juni 2002,2002, 2002.
|
Magnus Janzon, Lars-Åke Levin and Eva Swahn
Cost-effectiveness of early invasive treatment in unstable coronary artery disease: A one-year follow-up from the FRISC II invasive trial
Journal of the American College of Cardiology, 2001.
Web of Science® Times Cited: 1
|
Magnus Janzon, Lars-Åke Levin and Eva Swahn
Quality of life one year after invasive intervention in unstable coronary artery disease: Results from the FRISC II invasive trial
Journal of the American College of Cardiology, 2001.
|
Magnus Janzon, Lars-Åke Levin and Eva Swahn
Cast-comparison of early invasive versus non-invasive treatment in unstable coronary artery disease - A six months follow-up from the FRISC II invasive trial
Journal of the American College of Cardiology, 2000.
|
Magnus Janzon, Lars-Åke Levin and Eva Swahn
Quality of life in unstable coronary artery disease - A comparison of early invasive versus non-invasive treatment. Six months follow-up from the FRISC II invasive trial
Journal of the American College of Cardiology, 2000.
|
Ph.D. Theses
Reports
Lars-Åke Levin
QALY som effektmått inom vården. Möjligheter och begränsningar: Kapitel 4. Tillstånd med negativa QALY-vikter och mätning av temporära hälsotillstånd
CMT Rapport, 2012:2, 2012.
|
Lars Bernfort and Lars-Åke Levin
QALY som effektmått inom vården. Möjligheter och begränsningar: Kapitel 1. Bakgrund till QALY som effektmått
CMT Rapport, , 2012.
|
Per Carlsson, Mikael Hoffmann, Lars-Åke Levin, Lars Sandman and Johanna Wiss
Prioritering och finansiering av läkemedel för behandling av patienter med sällsynta sjukdomar
Prioriteringscentrum, 2012:1, 2012.
|
Lars-Åke Levin, David Andersson, Anders Anell, Emelie Heintz, Mikael Hoffman, Andrea Schmidt and Per Carlsson
Styrformer för effektiv läkemedelsanvändning
CMT Rapport, 2010:2, 2011.
Fulltext
|
Thomas Davidson, Magnus Husberg, Magnus Janzon and Lars-Åke Levin
CMT rapport: kostnader och kostnadseffektivitet av ett införande av dabigatran hos patienter med förmaksflimmer
CMT Rapport, 2011:1, 2011.
Fulltext
|
Mikael Rahmqvist, Lars-Åke Levin and Ulf Stenestrand
Utvärdering av Socialstyrelsens riktlinjer för prioritering i hjärtsjukvård 2001-2006
Rapport / PrioriteringsCentrum, 3, 2008.
|
Thomas Davidson and Lars-Åke Levin
Närståendes konsekvenser: Hur kan de inkluderas i den hälsoekonomiska analysen?
CMT Rapport, 2008:4, 2008.
Fulltext
|
Mikael Rahmqvist, Lars-Åke Levin and Ulf Stenestrand
Utvärdering av Socialstyrelsens riktlinjer för prioritering i hjärtsjukvård 2001-2004
2006.
|
Mari Berglind, Simone Ignatova, Lars-Åke Levin, Olle Larkö and Inger Rosdahl
Uppskattning av antal patienter med basalcellscancer i Sverige under 2003 samt kostnader för diagnostik och behandling
SSI-rapport / Statens strålskyddsinstitut - SSI ; Swedish Radiation Protection Institute, 7, 2006.
|
Thomas Davidson and Lars-Åke Levin
Kostnaden för förmaksflimmer i Östergötland
CMT Rapport, 2006:5, 2006.
Fulltext
|
Mikael Rahmqvist and Lars-Åke Levin
Hur påverkas sjukvården i praktiken? Utvärdering av Socialstyrelsens riktlinjer för prioritering av hjärtsjukvård. Utgångsläget 2001-2003
PrioriteringsCentrum, 5, 2005.
|
Bengt Jönsson, Göran Arvidsson, Lars-Åke Levin and Clas Rehnberg
Hälsa, vård och tillväxt
2004.
|
* Social media data based on publications from 2011 to present and with a DOI; data delivered by Altmetric.com.
Ph.D., Lic. Theses
